AI-generated · cited to primary sources · not investment advice
Eli Lilly and Company Common Stock (LLY) Mar 2025 Filing Analysis
Does management do what it says?
Capital expenditures have increased significantly, with $5.29 billion spent on property and equipment in the first nine months of 2025 compared to $3.56 billion in the prior year period, confirming the commitment to higher spend for manufacturing expansion. (2 in progress across 2 tracked commitments)
“Production increases and delivery presentation initiatives are ongoing, and additional capacity is expected to be operational over the next several years.”
The potential liability for contract manufacturing and supply agreements has increased to approximately $9 billion, up from the previously reported $8 billion. (1 revised across 1 tracked commitment)
“Executed agreements related to our medicines in development could, under certain circumstances, require us to pay up to approximately $8 billion if we do not purchase specified amounts of goods or services over the durations of the agreements, which are generally up to 8 years.”
See the full cited Management analysis of Eli Lilly and Company Common Stock
Where does growth come from?
While the document notes the impact of the Inflation Reduction Act (IRA) and government price setting for products like Jardiance starting in 2026, the specific 'Bridge Program' for Medicare obesity access is a forward-looking regulatory and market access shift currently in the planning/implementation phase. (2 new trend across 2 signals)
“In August 2023, HHS selected Jardiance... as one of the first ten medicines subject to government-set prices effective in 2026”
See the full cited Future Growth analysis of Eli Lilly and Company Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.